Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

216.55USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$216.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
308,300
52-wk High
$230.63
52-wk Low
$126.16

Select another date:

Thu, Dec 7 2017

BRIEF-Disney Board Elects Oracle And Illumina CEOs As Directors

* DISNEY BOARD ELECTS ORACLE’S SAFRA CATZ AND ILLUMINA’S FRANCIS A. DESOUZA AS DIRECTORS

BRIEF-Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

* Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

BRIEF-Illumina announces ‍introduction of its NextSeq 550Dx instrument

* Illumina Inc - ‍introduction of its NextSeq 550Dx instrument, co's second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system​

BRIEF-Illumina reports Q3 GAAP earnings per share $1.11

* Illumina reports financial results for third quarter of fiscal year 2017

BRIEF-Illumina files new patent infringement suit against Premaitha Health Plc

* Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK Source text for Eikon: Further company coverage:

Illumina shares sparkle on strong demand for new gene tech

Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

CORRECTED-UPDATE 1-Illumina shares sparkle on strong demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

Illumina shares sparkle on demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 12 percent on Wednesday, a day after the company raised its full-year revenue forecast on higher-than-expected demand for its new gene-sequencing technology.

BRIEF-Illumina Q2 earnings per share $0.87

* Illumina reports strong financial results for second quarter of fiscal year 2017

Illumina notches win in prenatal testing patent fight

A federal appeals court on Tuesday revived a patent on fetal diagnostic testing that Illumina Inc has accused rival Sequenom Inc of infringing.

Select another date: